Sight Sciences (SGHT)

What Moves the Stock

1. 01OMNI procedure volume growth and installed base expansion (number of active accounts performing procedures)
2. 02TearCare system placements and utilization rates (procedures per system per month)
3. 03Clinical trial readouts and FDA regulatory milestones for pipeline indications
4. 04Reimbursement policy changes affecting MIGS procedure codes or dry eye treatment coverage
5. 05Quarterly revenue beat/miss versus consensus estimates given high growth expectations
6. 06Cash burn rate and runway to profitability or need for additional financing
7. 07OMNI Surgical System (glaucoma treatment devices and consumables) - estimated 70-75% of revenue
8. 08TearCare System (dry eye treatment platform and single-use devices) - estimated 25-30% of revenue

SGHT Chart

My Notes

• growth - Attracts speculative growth investors and healthcare-focused funds willing to accept deep losses for potential market share gains…
• Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies…
• Watch on earnings: Medicare reimbursement rates for CPT codes 65820 (goniotomy) and 0671T/0672T (canaloplasty) procedures, Quarterly OMNI procedure volume growth rate (target: 20%+ YoY to justify valuation), TearCare system installed base and utilization trends (procedures per system per quarter).